/
/
/

Pfizer Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹653 Cr₹629 Cr₹645 Cr₹642 Cr₹603 Cr₹592 Cr₹538 Cr₹589 Cr₹563 Cr₹547 Cr₹540 Cr₹575 Cr₹531 Cr₹573 Cr₹622 Cr₹637 Cr₹593 Cr₹550 Cr₹676 Cr₹636 Cr₹749 Cr₹535 Cr₹593 Cr₹595 Cr₹515 Cr₹502 Cr₹538 Cr₹567 Cr₹544 Cr₹536 Cr₹514 Cr₹520 Cr₹512 Cr₹520 Cr₹457 Cr₹571 Cr₹433 Cr₹453 Cr₹510 Cr₹558 Cr₹521 Cr₹535 Cr₹506 Cr₹511 Cr₹483 Cr₹463 Cr₹474 Cr₹481 Cr₹435 Cr₹274 Cr₹272 Cr₹299 Cr₹266 Cr₹281 Cr₹256 Cr₹268 Cr
₹45 Cr₹41 Cr₹38 Cr₹42 Cr₹67 Cr₹45 Cr₹43 Cr₹43 Cr₹42 Cr₹75 Cr₹36 Cr₹36 Cr₹33 Cr₹31 Cr₹27 Cr₹24 Cr₹18 Cr₹17 Cr₹18 Cr₹15 Cr₹12 Cr₹37 Cr₹15 Cr₹12 Cr₹17 Cr₹45 Cr₹58 Cr₹45 Cr₹36 Cr₹35 Cr₹64 Cr₹37 Cr₹31 Cr₹31 Cr₹32 Cr₹24 Cr₹27 Cr₹29 Cr₹27 Cr₹24 Cr₹22 Cr₹29 Cr₹25 Cr₹17 Cr₹17 Cr₹19 Cr₹17 Cr₹15 Cr₹16 Cr₹16 Cr₹28 Cr₹34 Cr₹30 Cr₹31 Cr₹26 Cr₹23 Cr
₹698 Cr₹670 Cr₹683 Cr₹684 Cr₹670 Cr₹636 Cr₹581 Cr₹632 Cr₹605 Cr₹622 Cr₹576 Cr₹611 Cr₹565 Cr₹604 Cr₹649 Cr₹662 Cr₹611 Cr₹567 Cr₹694 Cr₹651 Cr₹761 Cr₹572 Cr₹608 Cr₹608 Cr₹532 Cr₹547 Cr₹596 Cr₹612 Cr₹580 Cr₹571 Cr₹578 Cr₹557 Cr₹543 Cr₹551 Cr₹489 Cr₹595 Cr₹460 Cr₹482 Cr₹537 Cr₹582 Cr₹542 Cr₹564 Cr₹530 Cr₹528 Cr₹500 Cr₹482 Cr₹491 Cr₹496 Cr₹452 Cr₹291 Cr₹300 Cr₹333 Cr₹297 Cr₹313 Cr₹283 Cr₹291 Cr
₹420 Cr₹408 Cr₹431 Cr₹427 Cr₹407 Cr₹381 Cr₹407 Cr₹414 Cr₹400 Cr₹371 Cr₹405 Cr₹408 Cr₹436 Cr₹417 Cr₹445 Cr₹432 Cr₹428 Cr₹418 Cr₹508 Cr₹474 Cr₹490 Cr₹436 Cr₹424 Cr₹420 Cr₹356 Cr₹422 Cr₹429 Cr₹428 Cr₹403 Cr₹402 Cr₹377 Cr₹408 Cr₹400 Cr₹399 Cr₹356 Cr₹420 Cr₹371 Cr₹375 Cr₹463 Cr₹483 Cr₹435 Cr₹427 Cr₹440 Cr₹409 Cr₹385 Cr₹372 Cr₹446 Cr₹415 Cr₹368 Cr₹204 Cr₹228 Cr₹227 Cr₹223 Cr₹228 Cr₹218 Cr₹213 Cr
₹292 Cr₹277 Cr₹266 Cr₹272 Cr₹277 Cr₹272 Cr₹189 Cr₹232 Cr₹219 Cr₹265 Cr₹188 Cr₹219 Cr₹144 Cr₹213 Cr₹231 Cr₹256 Cr₹210 Cr₹183 Cr₹213 Cr₹204 Cr₹298 Cr₹163 Cr₹211 Cr₹215 Cr₹203 Cr₹154 Cr₹192 Cr₹209 Cr₹202 Cr₹186 Cr₹219 Cr₹167 Cr₹161 Cr₹170 Cr₹150 Cr₹191 Cr₹104 Cr₹123 Cr₹89 Cr₹116 Cr₹123 Cr₹151 Cr₹105 Cr₹132 Cr₹130 Cr₹144 Cr₹78 Cr₹112 Cr₹116 Cr₹89 Cr₹75 Cr₹109 Cr₹75 Cr₹86 Cr₹66 Cr₹80 Cr
₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹7 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹4 Cr₹4 Cr₹5 Cr₹3 Cr₹4 Cr₹2 Cr₹3 Cr₹2 Cr₹61 L₹29 L₹22 L₹17 L-₹12 L₹20 L₹16 L₹18 L₹13 L₹23 L₹18 L₹42 L₹10 L₹23 L₹9 L₹10 L₹17 L₹15 L₹31 L₹14 L₹19 L₹8 L₹1 L₹8 L-₹7 L₹4 L₹15 L
₹277 Cr₹269 Cr₹192 Cr₹255 Cr₹260 Cr₹426 Cr₹172 Cr₹215 Cr₹203 Cr₹244 Cr₹176 Cr₹201 Cr₹126 Cr₹165 Cr₹201 Cr₹415 Cr₹43 Cr₹145 Cr₹184 Cr₹175 Cr₹269 Cr₹132 Cr₹180 Cr₹183 Cr₹173 Cr₹122 Cr₹165 Cr₹181 Cr₹175 Cr₹168 Cr₹201 Cr₹149 Cr₹142 Cr₹153 Cr₹132 Cr₹175 Cr₹89 Cr₹107 Cr₹92 Cr₹203 Cr₹115 Cr₹136 Cr₹90 Cr₹129 Cr₹116 Cr₹110 Cr₹41 Cr₹4 Cr₹84 Cr₹87 Cr₹73 Cr₹107 Cr₹73 Cr₹84 Cr₹96 Cr₹78 Cr
₹204 Cr₹200 Cr₹142 Cr₹189 Cr₹192 Cr₹331 Cr₹128 Cr₹158 Cr₹151 Cr₹179 Cr₹130 Cr₹149 Cr₹94 Cr₹130 Cr₹151 Cr₹311 Cr₹33 Cr₹126 Cr₹144 Cr₹143 Cr₹200 Cr₹101 Cr₹141 Cr₹131 Cr₹124 Cr₹103 Cr₹139 Cr₹154 Cr₹113 Cr₹109 Cr₹132 Cr₹96 Cr₹92 Cr₹105 Cr₹87 Cr₹111 Cr₹57 Cr₹68 Cr₹62 Cr₹126 Cr₹80 Cr₹87 Cr₹60 Cr₹83 Cr₹75 Cr₹43 Cr₹18 Cr₹2 Cr₹38 Cr₹56 Cr₹48 Cr₹70 Cr₹48 Cr₹58 Cr₹64 Cr₹52 Cr

Share Price Live Stats

Open (₹)4,680.00
Volume (₹)10,609.00
High (₹)4,695.00
Upper Circuit5,553.10
Low (₹)4,601.00
Lower Circuit3,702.10
Prev Close4,627.60
52W High (₹)5,578.50
Price4,643.70
52W Low (₹)4,360.10

Share Market Cap & Key Ratios Overview

M.Cap (₹)21168.20 Cr
Div. Yield (%)1.62
PE Ratio28.79
Debt to Equity0.00
Price to Book5.14
Book Value918.67
EPS (TTM)160.70
Face Value10.00
ROE (%)17.16

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
PFIZERNSE
LTP
1W Low
1W High
Market cap (₹)
1916-4 (-0.21%)
1905
1984.80
4,63,791Cr
9250+11 (0.12%)
9087
9467
2,45,081Cr
4905.5-144.5 (-2.86%)
4886.50
5066
1,90,351Cr
1143-48 (-4.03%)
1130.50
1187
1,14,833Cr
1394.7-28.8 (-2.02%)
1389.40
1426.10
1,14,163Cr
1868.5-70 (-3.61%)
1811.70
1949
1,00,660Cr
2132-39.5 (-1.82%)
2132
2192
98,431Cr
2368.8-14.1 (-0.59%)
2341.20
2419.20
98,305Cr
1155-23 (-1.95%)
1154.40
1179.90
96,906Cr
1637.3-8 (-0.49%)
1626.60
1717
95,300Cr
4643.7-60.1 (-1.28%)
4601
4732.10
21,168Cr

Key Highlights of Pfizer Ltd’s P&L

In 2008-11-30, Pfizer Ltd reported total revenue of ₹807.93Cr, compared with ₹1058.38Cr in 2007-11-30, reflecting Pfizer Ltd turnover.

Depreciation was ₹11.12Cr and finance costs were ₹0 crore in 2008-11-30

Profit Before Tax (PBT) has been ₹419.13Cr in 2008-11-30 as compared to ₹451.34Cr in 2007-11-30.

Net Profit (PAT) was ₹299.57Cr in 2008-11-30 compared with ₹340Cr in 2007-11-30.

Earnings per share (EPS) were ₹100.39 in 2008-11-30, compared with ₹113.94 in 2007-11-30.